市場調查報告書

生物製劑合同生產的全球市場:強大的生物製劑管道可推動市場快速增長

Global Market Study on Biologics Contract Manufacturing Demand: Strong Biologics Pipeline to Rapidly Surge Market Growth

出版商 Persistence Market Research 商品編碼 968206
出版日期 內容資訊 英文 293 Pages
商品交期: 2-3個工作天內
價格
生物製劑合同生產的全球市場:強大的生物製劑管道可推動市場快速增長 Global Market Study on Biologics Contract Manufacturing Demand: Strong Biologics Pipeline to Rapidly Surge Market Growth
出版日期: 2020年09月25日內容資訊: 英文 293 Pages
簡介

本報告調查了全球生物製劑合同製造市場,包括市場概況,主要趨勢和成功因素,市場背景,新冠狀病毒感染(COVID-19)危機的影響分析,市場趨勢,價格分析,容量和需求分析和預測,平台,處理區域,應用程序,技術,區域,國家分析和預測,市場結構分析,競爭狀況分析,公司提供配置文件等信息。

目錄

第1章執行摘要

第2章市場概述

第3章主要市場趨勢

  • 影響市場的主要趨勢
  • 產品發展趨勢

第4章市場背景

  • 宏觀經濟因素
    • 全球GDP增長展望
    • 全球醫療成本展望
    • 新興國家醫療部門的增長
  • 預測因素:相關性和影響
    • 全球醫療費用增加
    • 強大的生物製劑產品線可促進市場擴展
    • 風險資本投資以支持生物技術研發
    • 阻礙合同生物製藥生產市場增長的法規變化
    • 對合同製造成本的影響
    • 監管情況
  • 市場動態
    • 促進因素
    • 抑製器
    • 市場機會分析

第5章COVID-19危機影響分析

  • COVID-19危機影響分析
    • 當前統計數據和預期的未來影響
    • 當前GDP預測和預期影響
    • 與2008年經濟分析相比的當前經濟預測
    • COVID-19和影響分析
  • 容量分析
    • 在COVID-19危機之前,現在,在COVID-19危機之後
    • 擴大COVID-19相關產品的生產能力
  • 需求分析
    • 在COVID-19危機之前,現在,在COVID-19危機之後
    • 基於COVID-19的影響進行價格分析
    • 利用率分析
    • 2020年的市場前景
    • 季度預測
    • 季度有望恢復
  • 對趨勢分析的影響
    • 一次性使用
    • 模塊
    • 整合
  • 恢復情景:短期,中期,長期影響

第6章市場情況

  • 產品採用/使用情況分析
  • 大公司的促銷策略
  • 主要交易
  • 監管情況

第7章容量分析和預測

  • 到目前為止的產能分析
  • 當前和未來產能的預測

第8章價格分析

  • 每個地區的價格分析:按服務
  • 全球平均價格分析基準

第9章全球需求分析和預測

  • 到目前為止的市場分析
  • 當前和未來的市場預測
    • 同比增長趨勢分析

第10章產品分析和預測

  • 簡介/主要發現
  • 過去的市場
  • 當前和未來的市場預測
    • 生長因子
    • 干擾素
    • 單克隆抗體
    • 重組激素
    • 疫苗
    • 胰島素
    • 其他
  • 市場吸引力分析

第11章特定於平台的分析和預測

  • 簡介/主要發現
  • 過去的市場
  • 當前和未來的市場預測
    • 哺乳動物
    • 微生物
  • 市場吸引力分析

第12章按治療區域進行分析和預測

  • 簡介/主要發現
  • 過去的市場
  • 當前和未來的市場預測
    • 自身免疫性疾病
    • 腫瘤
    • 代謝性疾病
    • 眼疾
    • 心血管疾病
    • 傳染病
    • 神經系統疾病
    • 呼吸系統疾病
    • 其他
  • 市場吸引力分析

第13章按應用進行分析和預測

  • 簡介/主要發現
  • 過去的市場
  • 當前和未來的市場預測
    • 臨床用途
    • 商業用途
  • 市場吸引力分析

第14章區域分析和預測

  • 簡介/主要發現
  • 過去的市場
  • 當前和未來的市場預測
    • 北美
    • 拉丁美洲
    • 歐洲
    • 東亞
    • 南亞
    • 大洋洲
    • 中東/非洲
  • 市場吸引力分析

第15章北美需求分析和預測

  • 簡介
  • 到目前為止的市場趨勢分析
  • 市場預測
    • 按國家
    • 副產品
    • 按平台
    • 按治療區域
    • 按應用
  • 市場吸引力分析

第16章拉丁美洲需求分析和預測

  • 簡介
  • 到目前為止的市場趨勢分析
  • 市場預測
    • 按國家
    • 副產品
    • 按平台
    • 按治療區域
    • 按應用
  • 市場吸引力分析

第17章歐洲需求分析和預測

  • 簡介
  • 到目前為止的市場趨勢分析
  • 市場預測
    • 按國家
    • 副產品
    • 按平台
    • 按治療區域
    • 按應用
  • 市場吸引力分析

第18章南亞需求分析和預測

  • 簡介
  • 到目前為止的市場趨勢分析
  • 市場預測
    • 按國家
    • 副產品
    • 按平台
    • 按治療區域
    • 按應用
  • 市場吸引力分析

第19章東亞需求分析和預測

  • 簡介
  • 到目前為止的市場趨勢分析
  • 市場預測
    • 按國家
    • 副產品
    • 按平台
    • 按治療區域
    • 按應用
  • 市場吸引力分析

第20章大洋洲的需求分析和預測

  • 簡介
  • 到目前為止的市場趨勢分析
  • 市場預測
    • 按國家
    • 副產品
    • 按平台
    • 按治療區域
    • 按應用
  • 市場吸引力分析

第21章中東和非洲的需求分析和預測

  • 簡介
  • 到目前為止的市場趨勢分析
  • 市場預測
    • 按國家
    • 副產品
    • 按平台
    • 按治療區域
    • 按應用
  • 市場吸引力分析

第22章主要市場和新興市場的分析和預測

  • 美國
  • 加拿大
  • 英國
  • 德國
  • 法國
  • 西班牙
  • 意大利

第23章市場結構分析

  • 市場分析:公司分層
  • 主要公司的市場份額分析
  • 市場集中度
  • 市場佔有率分析
    • 區域足跡
    • 產品佔地面積
    • 渠道足跡

第24章競爭分析

  • 競爭儀表板
  • 潛力和能力分析
  • 競爭分析
    • BioXcellence (Boehringer Ingelheim GmbH)
    • Lonza Group AG
    • Samsung Biologics Co. Ltd.
    • Fujifilm Diosynth Biotechnologies (FUJIFILM Holdings)
    • AbbVie Contract Manufacturing (AbbVie Inc.)
    • WuXi Biologics (Cayman) Inc.
    • Patheon N.V. (Thermo Fisher Scientific Inc.)
    • Emergent BioSolutions Inc.
    • AGC Biologics
    • Ajinomoto Bio-Pharma (Ajinomoto Co., Inc.)
    • Avid Bioservices, Inc.
    • KBI Biopharma (JSR Life Sciences (JLS))
    • Catalent Inc.
    • Abzena Plc.

第25章先決條件和首字母縮寫詞

第26章調查方法

目錄
Product Code: PMRREP31928

Biologics Contract Manufacturing Demand - Scope of the Report

Persistence Market Research (PMR) recently published a market study on the global market for biologics contract manufacturing demand. The study provides detailed assessment on key market dynamics, including the drivers, trends, opportunities, restraints, and detailed information about the biologics contract manufacturing demand structure. The market study presents exclusive information about how biologics contract manufacturing demand will grow during the forecast period of 2020-2030.

Key indicators of market growth, which include Year-on-Year (Y-o-Y) growth of the market, and compounded annual growth rate (CAGR) are explained in PMR's study in a comprehensive manner. This information can help readers understand the quantitative growth prospects of biologics contract manufacturing demand during the forecast period.

The study is relevant for stakeholders interested in biologics contract manufacturing demand, including biologics contract manufacturing service organizations, suppliers, distributors, and investors, and can help them in developing appropriate strategies to grow in the market. Stakeholders in biologics contract manufacturing demand, investors, industry experts, researchers, and journalists, as well as business researchers can leverage the information and data presented in PMR's study.

The study also includes statistics as well as facts related to the macro- as well as micro-economic factors that are impacting developments in the market. It also offers actionable insights based on the future trends regarding biologics contract manufacturing demand. Furthermore, small businesses and new entrants related to biologics contract manufacturing demand too can make use of the information presented in this study, based on which, they can make appropriate business decisions to gain momentum in the market.

Key Questions Answered in PMR's Biologics Contract Manufacturing Demand Study

How will CDMO services demand unfold over the coming years?

Which regions will continue to remain the most profitable regional markets for players dealing with biologics contract manufacturing demand?

Which factors will induce a change in biologics contract manufacturing demand during the assessment period?

How will changing trends impact biologics contract manufacturing demand?

How can market players capture the low-hanging opportunities related to biologics contract manufacturing demand in developed regions?

Which companies are leading in biologics contract manufacturing demand?

What are the winning strategies of stakeholders involved in biologics contract manufacturing demand services to upscale their position in this landscape?

Biologics Contract Manufacturing Demand: Research Methodology

In PMR's study, a unique research methodology is utilized to conduct extensive research on the growth of biologics contract manufacturing demand, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts ensure the accuracy and reliability of the conclusions.

Secondary resources referred to by analysts during the production of the biologics contract manufacturing demand market study include statistics from government organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.

Comprehensive information acquired from primary and secondary resources acts as a validation from companies dealing in biologics contract manufacturing demand, and makes PMR's projections on the growth prospects of the market space more accurate and reliable.

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply Side Trends
  • 1.4. Competitive Snapshot, Capacity (kL)
  • 1.5. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations

3. Key Market Trends

  • 3.1. Key Trends Impacting The Market
  • 3.2. Product Development Trends

4. Market Background

  • 4.1. Macro-Economic Factors
    • 4.1.1. Global GDP Growth Outlook
    • 4.1.2. Global Healthcare Expenditure Outlook
    • 4.1.3. Growth of Healthcare Sector in Emerging Nations
  • 4.2. Forecast Factors - Relevance & Impact
    • 4.2.1. Global Increase in Healthcare Expenditure
    • 4.2.2. Strong biologics pipeline fuel demand for the CMOs
    • 4.2.3. Corporate Venture Capital Investments are Helping Advance Biotechnology R&D
    • 4.2.4. Changing regulatory dynamics are hampering the growth of Biopharmaceutical contract manufacturing market
    • 4.2.5. CMO Cost Impact
    • 4.2.6. Regulatory Scenario
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunity Analysis

5. COVID19 Crisis Impact Analysis

  • 5.1. COVID19 Crisis Impact Analysis
    • 5.1.1. Current COVID19 Statistics and Probable Future Impact
    • 5.1.2. Current GDP Projection and Probable Impact
    • 5.1.3. Current Economic Projection as compared to 2008 Economic analysis
    • 5.1.4. COVID19 and Impact Analysis
  • 5.2. Biopharmaceutical Contract Manufacturing Market Capacity Analysis
    • 5.2.1. Historical (pre-COVID), Current (during-COVID), Future (post-COVID)
      • 5.2.1.1. By Product
      • 5.2.1.2. By Therapeutic Area
      • 5.2.1.3. By Platform
      • 5.2.1.4. By Application
      • 5.2.1.5. By Region (including especially EU/U.K./U.S.)
    • 5.2.2. Manufacturing Capacity Expansion for COVID-19 Related Products
  • 5.3. Biopharmaceutical Contract Manufacturing Market Demand Analysis
    • 5.3.1. Historical (pre-COVID), Current (during-COVID), Future (post-COVID)
      • 5.3.1.1. By Product
      • 5.3.1.2. By Therapeutic Area
      • 5.3.1.3. By Platform
      • 5.3.1.4. By Application
      • 5.3.1.5. By Region (including especially EU/U.K./U.S.)
    • 5.3.2. Covid-19 Impact Pricing Analysis
      • 5.3.2.1. Historical (pre-COVID), Current (during-COVID), Future (post-COVID)
    • 5.3.3. Capacity Utilization Analysis
      • 5.3.3.1. Initiation of COVID-19 related Products Contract Manufacturing
      • 5.3.3.2. Timeframe of Capacity and Slot Utilization for COVID-related Products
    • 5.3.4. 2020 Market Scenario
    • 5.3.5. Quarter by Quarter Forecast
    • 5.3.6. Projected Recovery Quarter
  • 5.4. Impact on Trends Analysis
    • 5.4.1. Single-Use
    • 5.4.2. Modular
    • 5.4.3. Consolidation
  • 5.5. Recovery Scenario - Short term, Midterm and Long Term Impact

6. Market Context

  • 6.1. Product Adoption / Usage Analysis
  • 6.2. Promotional Strategies by Key Players
  • 6.3. Key Industry Deals
  • 6.4. Regulatory Scenario

7. Global Biopharmaceutical Contract Manufacturing Market Capacity (in kL/Units) Analysis 2015-2019 and Forecast, 2020-2030

  • 7.1. Historical Market Capacity (in kL/Units) Analysis, 2015-2019
  • 7.2. Current and Future Market Capacity (kL/Units) Projections, 2020-2030
    • 7.2.1. Y-o-Y Growth Trend Analysis
    • 7.2.2. Absolute Capacity (in kL/Units) Opportunity Analysis

8. Global Biopharmaceutical Contract Manufacturing Market - Pricing Analysis

  • 8.1. Regional Pricing Analysis, By Services
  • 8.2. Global Average Pricing Analysis Benchmark

9. Global Biopharmaceutical Contract Manufacturing Market Demand (in Value or Size in US$ Mn) Analysis 2015-2019 and Forecast, 2020-2030

  • 9.1. Historical Market Value (US$ Mn) Analysis, 2015-2019
  • 9.2. Current and Future Market Value (US$ Mn) Projections, 2020-2030
    • 9.2.1. Y-o-Y Growth Trend Analysis
    • 9.2.2. Absolute $ Opportunity Analysis

10. Global Biopharmaceutical Contract Manufacturing Capacity Analysis 2015-2019 and Forecast 2020-2030, by Product

  • 10.1. Introduction / Key Findings
  • 10.2. Historical Market Capacity (in kL) Analysis By Product, 2015 - 2019
  • 10.3. Current and Future Market Capacity (in kL) Analysis and Forecast By Product, 2020 - 2030
    • 10.3.1. Growth Factors
    • 10.3.2. Interferons
    • 10.3.3. Monoclonal Antibodies
    • 10.3.4. Recombinant Hormones
    • 10.3.5. Vaccines
    • 10.3.6. Insulin
    • 10.3.7. Others
  • 10.4. Market Attractiveness Analysis By Product

11. Global Biopharmaceutical Contract Manufacturing Capacity Analysis 2015-2019 and Forecast 2020-2030, By Platform

  • 11.1. Introduction / Key Findings
  • 11.2. Historical Market Capacity (in kL) Analysis By Platform, 2015 - 2019
  • 11.3. Current and Future Market Capacity (in kL) Analysis and Forecast By Platform, 2020 - 2030
    • 11.3.1. Mammalian
    • 11.3.2. Microbial
  • 11.4. Market Attractiveness Analysis By Platform

12. Global Biopharmaceutical Contract Manufacturing Capacity Analysis 2015-2019 and Forecast 2020-2030, By Therapeutic Area

  • 12.1. Introduction / Key Findings
  • 12.2. Historical Market Capacity (in kL) Analysis By Therapeutic Area, 2015 - 2019
  • 12.3. Current and Future Market Capacity (in kL) Analysis and Forecast By Therapeutic Area, 2020 - 2030
    • 12.3.1. Autoimmune Diseases
    • 12.3.2. Oncology
    • 12.3.3. Metabolic Diseases
    • 12.3.4. Ophthalmology
    • 12.3.5. Cardiovascular Diseases
    • 12.3.6. Infectious Diseases
    • 12.3.7. Neurology
    • 12.3.8. Respiratory Disorders
    • 12.3.9. Others
  • 12.4. Market Attractiveness Analysis By Therapeutic Area

13. Global Biopharmaceutical Contract Manufacturing Capacity Analysis 2015-2019 and Forecast 2020-2030, By Application

  • 13.1. Introduction / Key Findings
  • 13.2. Historical Market Capacity (in kL) Analysis By Application, 2015 - 2019
  • 13.3. Current and Future Market Capacity (in kL) Analysis and Forecast By Application, 2020 - 2030
    • 13.3.1. Clinical
    • 13.3.2. Commercial
  • 13.4. Market Attractiveness Analysis By Application

14. Global Biopharmaceutical Contract Manufacturing Capacity Analysis 2015-2019 and Forecast 2020-2030, by Region

  • 14.1. Introduction
  • 14.2. Historical Market Capacity (in kL) Analysis By Region, 2015 - 2019
  • 14.3. Current Market Capacity (in kL) Analysis and Forecast By Region, 2020 - 2030
    • 14.3.1. North America
    • 14.3.2. Latin America
    • 14.3.3. Europe
    • 14.3.4. East Asia
    • 14.3.5. South Asia
    • 14.3.6. Oceania
    • 14.3.7. Middle East and Africa (MEA)
  • 14.4. Market Attractiveness Analysis By Region

15. North America Biopharmaceutical Contract Manufacturing Demand Analysis 2015-2019 and Forecast 2020-2030

  • 15.1. Introduction
  • 15.2. Historical Market Capacity (in kL) Trend Analysis By Taxonomy, 2015 - 2019
  • 15.3. Market Capacity (in kL) Forecast By Taxonomy, 2020 - 2030
    • 15.3.1. By Country
      • 15.3.1.1. U.S.
      • 15.3.1.2. Canada
    • 15.3.2. By Product
    • 15.3.3. By Platform
    • 15.3.4. By Therapeutic Area
    • 15.3.5. By Application
  • 15.4. Market Attractiveness Analysis

16. Latin America Biopharmaceutical Contract Manufacturing Demand Analysis 2015-2019 and Forecast 2020-2030

  • 16.1. Introduction
  • 16.2. Historical Market Capacity (in kL) Trend Analysis By Taxonomy, 2015 - 2019
  • 16.3. Market Size Capacity (in kL) Forecast By Taxonomy, 2020 - 2030
    • 16.3.1. By Country
      • 16.3.1.1. Brazil
      • 16.3.1.2. Mexico
      • 16.3.1.3. Argentina
      • 16.3.1.4. Rest of Latin America
    • 16.3.2. By Product
    • 16.3.3. By Platform
    • 16.3.4. By Therapeutic Area
    • 16.3.5. By Application
  • 16.4. Market Attractiveness Analysis

17. Europe Biopharmaceutical Contract Manufacturing Demand Analysis 2015-2019 and Forecast 2020-2030

  • 17.1. Introduction
  • 17.2. Historical Market Capacity (in kL) Trend Analysis By Taxonomy, 2015 - 2019
  • 17.3. Market Capacity (in kL) Forecast By Market, 2020 - 2030
    • 17.3.1. By Country
      • 17.3.1.1. Germany
      • 17.3.1.2. Italy
      • 17.3.1.3. France
      • 17.3.1.4. U.K.
      • 17.3.1.5. Spain
      • 17.3.1.6. BENELUX
      • 17.3.1.7. Russia
      • 17.3.1.8. Rest of Europe
    • 17.3.2. By Product
    • 17.3.3. By Platform
    • 17.3.4. By Therapeutic Area
    • 17.3.5. By Application
  • 17.4. Market Attractiveness Analysis

18. South Asia Biopharmaceutical Contract Manufacturing Demand Analysis 2015-2019 and Forecast 2020-2030

  • 18.1. Introduction
  • 18.2. Historical Market Capacity (in kL) Trend Analysis By Taxonomy, 2015 - 2019
  • 18.3. Market Capacity (in kL) Forecast By Taxonomy, 2020 - 2030
    • 18.3.1. By Country
      • 18.3.1.1. India
      • 18.3.1.2. Thailand
      • 18.3.1.3. Indonesia
      • 18.3.1.4. Malaysia
      • 18.3.1.5. Rest of South Asia
    • 18.3.2. By Product
    • 18.3.3. By Platform
    • 18.3.4. By Therapeutic Area
    • 18.3.5. By Application
  • 18.4. Market Attractiveness Analysis

19. East Asia Biopharmaceutical Contract Manufacturing Demand Analysis 2015-2019 and Forecast 2020-2030

  • 19.1. Introduction
  • 19.2. Historical Market Capacity (in kL) Trend Analysis By Taxonomy, 2015 - 2019
  • 19.3. Market Size Capacity (in kL) Forecast By Taxonomy, 2020 - 2030
    • 19.3.1. By Country
      • 19.3.1.1. China
      • 19.3.1.2. Japan
      • 19.3.1.3. South Korea
    • 19.3.2. By Product
    • 19.3.3. By Platform
    • 19.3.4. By Therapeutic Area
    • 19.3.5. By Application
  • 19.4. Market Attractiveness Analysis

20. Oceania Biopharmaceutical Contract Manufacturing Demand Analysis 2015-2019 and Forecast 2020-2030

  • 20.1. Introduction
  • 20.2. Historical Market Capacity (in kL) Trend Analysis By Taxonomy, 2015 - 2019
  • 20.3. Market Capacity (in kL) Forecast By Taxonomy, 2020 - 2030
    • 20.3.1. By Country
      • 20.3.1.1. Australia
      • 20.3.1.2. New Zealand
    • 20.3.2. By Product
    • 20.3.3. By Platform
    • 20.3.4. By Therapeutic Area
    • 20.3.5. By Application
  • 20.4. Market Attractiveness Analysis

21. Middle East and Africa Biopharmaceutical Contract Manufacturing Demand Analysis 2015-2019 and Forecast 2020-2030

  • 21.1. Introduction
  • 21.2. Historical Market Capacity (in kL) Trend Analysis By Taxonomy, 2015 - 2019
  • 21.3. Market Capacity (in kL) Forecast By Taxonomy, 2020 - 2030
    • 21.3.1. By Country
      • 21.3.1.1. GCC Countries
      • 21.3.1.2. South Africa
      • 21.3.1.3. Rest of Middle East and Africa
    • 21.3.2. By Product
    • 21.3.3. By Platform
    • 21.3.4. By Therapeutic Area
    • 21.3.5. By Application
  • 21.4. Market Attractiveness Analysis

22. Key and Emerging Countries Biopharmaceutical Contract Manufacturing Demand Analysis 2015-2019 and Forecast 2020-2030

  • 22.1. U.S. Biopharmaceutical Contract Manufacturing Demand Analysis
    • 22.1.1. By Product
    • 22.1.2. By Platform
    • 22.1.3. By Therapeutic Area
    • 22.1.4. By Application
  • 22.2. Canada Biopharmaceutical Contract Manufacturing Demand Analysis
    • 22.2.1. By Product
    • 22.2.2. By Platform
    • 22.2.3. By Therapeutic Area
    • 22.2.4. By Application
  • 22.3. U.K. Biopharmaceutical Contract Manufacturing Demand Analysis
    • 22.3.1. By Product
    • 22.3.2. By Platform
    • 22.3.3. By Therapeutic Area
    • 22.3.4. By Application
  • 22.4. Germany Biopharmaceutical Contract Manufacturing Demand Analysis
    • 22.4.1. By Product
    • 22.4.2. By Platform
    • 22.4.3. By Therapeutic Area
    • 22.4.4. By Application
  • 22.5. France Biopharmaceutical Contract Manufacturing Demand Analysis
    • 22.5.1. By Product
    • 22.5.2. By Platform
    • 22.5.3. By Therapeutic Area
    • 22.5.4. By Application
  • 22.6. Spain Biopharmaceutical Contract Manufacturing Demand Analysis
    • 22.6.1. By Product
    • 22.6.2. By Platform
    • 22.6.3. By Therapeutic Area
    • 22.6.4. By Application
  • 22.7. Italy Biopharmaceutical Contract Manufacturing Demand Analysis
    • 22.7.1. By Product
    • 22.7.2. By Platform
    • 22.7.3. By Therapeutic Area
    • 22.7.4. By Application

23. Market Structure Analysis

  • 23.1. Market Analysis by Tier of Companies
  • 23.2. Market Share Analysis of Top Players
  • 23.3. Market Concentration
  • 23.4. Market Presence Analysis
    • 23.4.1. By Regional Footprint of Players
    • 23.4.2. Product Footprint by Players
    • 23.4.3. Channel Footprint by Players

24. Competition Analysis

  • 24.1. Competition Dashboard
  • 24.2. CDMO Capability & Capacity Analysis 2020
  • 24.3. Competition Deep Dive
    • 24.3.1. BioXcellence (Boehringer Ingelheim GmbH)
      • 24.3.1.1. Overview
      • 24.3.1.2. Product Portfolio
      • 24.3.1.3. Key Financial
      • 24.3.1.4. Sales Footprint
      • 24.3.1.5. Analyst commentary
    • 24.3.2. Lonza Group AG
      • 24.3.2.1. Overview
      • 24.3.2.2. Product Portfolio
      • 24.3.2.3. Key Financial
      • 24.3.2.4. Sales Footprint
      • 24.3.2.5. Analyst commentary
    • 24.3.3. Samsung Biologics Co. Ltd.
      • 24.3.3.1. Overview
      • 24.3.3.2. Product Portfolio
      • 24.3.3.3. Key Financial
      • 24.3.3.4. Sales Footprint
      • 24.3.3.5. Analyst commentary
    • 24.3.4. Fujifilm Diosynth Biotechnologies (FUJIFILM Holdings)
      • 24.3.4.1. Overview
      • 24.3.4.2. Product Portfolio
      • 24.3.4.3. Key Financial
      • 24.3.4.4. Sales Footprint
      • 24.3.4.5. Analyst commentary
    • 24.3.5. AbbVie Contract Manufacturing (AbbVie Inc.)
      • 24.3.5.1. Overview
      • 24.3.5.2. Product Portfolio
      • 24.3.5.3. Key Financial
      • 24.3.5.4. Sales Footprint
      • 24.3.5.5. Analyst commentary
    • 24.3.6. WuXi Biologics (Cayman) Inc.
      • 24.3.6.1. Overview
      • 24.3.6.2. Product Portfolio
      • 24.3.6.3. Key Financial
      • 24.3.6.4. Sales Footprint
      • 24.3.6.5. Analyst commentary
    • 24.3.7. Patheon N.V. (Thermo Fisher Scientific Inc.)
      • 24.3.7.1. Overview
      • 24.3.7.2. Product Portfolio
      • 24.3.7.3. Key Financial
      • 24.3.7.4. Sales Footprint
      • 24.3.7.5. Analyst commentary
    • 24.3.8. Emergent BioSolutions Inc.
      • 24.3.8.1. Overview
      • 24.3.8.2. Product Portfolio
      • 24.3.8.3. Key Financial
      • 24.3.8.4. Sales Footprint
      • 24.3.8.5. Analyst commentary
    • 24.3.9. AGC Biologics
      • 24.3.9.1. Overview
      • 24.3.9.2. Product Portfolio
      • 24.3.9.3. Key Financial
      • 24.3.9.4. Sales Footprint
      • 24.3.9.5. Analyst commentary
    • 24.3.10. Ajinomoto Bio-Pharma (Ajinomoto Co., Inc.)
      • 24.3.10.1. Overview
      • 24.3.10.2. Product Portfolio
      • 24.3.10.3. Key Financial
      • 24.3.10.4. Sales Footprint
      • 24.3.10.5. Analyst commentary
    • 24.3.11. Avid Bioservices, Inc.
      • 24.3.11.1. Overview
      • 24.3.11.2. Product Portfolio
      • 24.3.11.3. Key Financial
      • 24.3.11.4. Sales Footprint
      • 24.3.11.5. Analyst commentary
    • 24.3.12. KBI Biopharma (JSR Life Sciences (JLS))
      • 24.3.12.1. Overview
      • 24.3.12.2. Product Portfolio
      • 24.3.12.3. Key Financial
      • 24.3.12.4. Sales Footprint
      • 24.3.12.5. Analyst commentary
    • 24.3.13. Catalent Inc.
      • 24.3.13.1. Overview
      • 24.3.13.2. Product Portfolio
      • 24.3.13.3. Key Financial
      • 24.3.13.4. Sales Footprint
      • 24.3.13.5. Analyst commentary
    • 24.3.14. Abzena Plc.
      • 24.3.14.1. Overview
      • 24.3.14.2. Product Portfolio
      • 24.3.14.3. Key Financial
      • 24.3.14.4. Sales Footprint
      • 24.3.14.5. Analyst commentary

25. Assumptions and Acronyms Used

26. Research Methodology

  • Table 01: Global Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Product
  • Table 02: Global Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Product
  • Table 03: Global Biologics Contract Manufacturing Demand Value (US$ Mn) Analysis and Opportunity Assessment 2015-2030, By Product
  • Table 04: Global Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Platform
  • Table 05: Global Biologics Contract Manufacturing Demand Value (US$ Mn) Analysis and Opportunity Assessment 2015-2030, By Platform
  • Table 06: Global Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Therapeutic Area
  • Table 07: Global Biologics Contract Manufacturing Demand Value (US$ Mn) Analysis and Opportunity Assessment 2015-2030, By Therapeutic Area
  • Table 08: Global Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Application
  • Table 09: Global Biologics Contract Manufacturing Demand Value (US$ Mn) Analysis and Opportunity Assessment 2015-2030, By Application
  • Table 10: Global Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Region
  • Table 11: Global Biologics Contract Manufacturing Demand Value (US$ Mn) Analysis and Opportunity Assessment 2015-2030, By Region
  • Table 12: North America Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Country
  • Table 13: North America Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Product
  • Table 14: North America Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Platform
  • Table 15: North America Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Therapeutic Area
  • Table 16: North America Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Application
  • Table 17: Latin America Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Product
  • Table 18: Latin America Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Platform
  • Table 19: Latin America Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Therapeutic Area
  • Table 20: Latin America Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Application
  • Table 21: Europe Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Country
  • Table 22: Europe Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Product
  • Table 23: Europe Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Platform
  • Table 24: Europe Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Therapeutic Area
  • Table 25: Europe Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Application
  • Table 26: South Asia Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Country
  • Table 27: South Asia Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Product
  • Table 28: South Asia Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Platform
  • Table 29: South Asia Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Therapeutic Area
  • Table 30: South Asia Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Application
  • Table 31: East Asia Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Country
  • Table 32: East Asia Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Product
  • Table 33: East Asia Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Platform
  • Table 34: East Asia Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Therapeutic Area
  • Table 35: East Asia Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Application
  • Table 36: Oceania Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Country
  • Table 37: Oceania Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Product
  • Table 38: Oceania Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Platform
  • Table 39: Oceania Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Therapeutic Area
  • Table 40: Oceania Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Application
  • Table 41: Middle East & Africa (MEA) Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Country
  • Table 42: Middle East & Africa (MEA) Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Product
  • Table 43: Middle East & Africa (MEA) Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Platform
  • Table 44: Middle East & Africa (MEA) Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Therapeutic Area
  • Table 45: Middle East & Africa (MEA) Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Application
  • Table 46: U. S. Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Product
  • Table 47: U. S. Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Platform
  • Table 48: U. S. Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Therapeutic Area
  • Table 49: U. S. Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Application
  • Table 50: Canada Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Product
  • Table 51: Canada Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Platform
  • Table 52: Canada Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Therapeutic Area
  • Table 53: Canada Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Application
  • Table 54: U. K. Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Product
  • Table 55: U. K. Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Platform
  • Table 56: U. K. Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Therapeutic Area
  • Table 57: U. K. Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Application
  • Table 58: Germany Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Product
  • Table 59: Germany Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Platform
  • Table 60: Germany Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Therapeutic Area
  • Table 61: Germany Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Application
  • Table 62: France Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Product
  • Table 63: France Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Platform
  • Table 64: France Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Therapeutic Area
  • Table 65: France Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Application
  • Table 66: Spain Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Product
  • Table 67: Spain Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Platform
  • Table 68: Spain Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Therapeutic Area
  • Table 69: Spain Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Application
  • Table 70: Italy Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Product
  • Table 71: Italy Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Platform
  • Table 72: Italy Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Therapeutic Area
  • Table 73: Italy Biologics Contract Manufacturing Demand Capacity (kL) Analysis and Opportunity Assessment 2015-2030, By Application
  • Figure 01: Global Biologics Contract Manufacturing Demand Capacity (kL) Analysis, 2015-2019
  • Figure 02: Global Biologics Contract Manufacturing Demand Capacity Forecast (kL), 2020-2030
  • Figure 03: Commercial Contract Manufacturing Pricing Analysis (US$) for 1kL Batch Size, By Region, 2020
  • Figure 04: Clinical Contract Manufacturing Pricing Analysis (US$) for 1kL Batch Size, By Region, 2020
  • Figure 05: Global Biologics Contract Manufacturing Demand Value Analysis (US$ Mn), 2015-2019
  • Figure 06: Global Biologics Contract Manufacturing Demand Value Forecast (US$ Mn), 2020-2030
  • Figure 07: Global Biologics Contract Manufacturing Demand Absolute $ Opportunity, 2020 - 2030
  • Figure 08: Global Biologics Contract Manufacturing Demand Share Analysis (%), By Product, 2020-2030
  • Figure 09: Global Biologics Contract Manufacturing Demand Y-o-Y Analysis (%), By Product, 2020-2030
  • Figure 10: Global Biologics Contract Manufacturing Demand Capacity Attractiveness Analysis By Product, 2020-2030
  • Figure 11: Global Biologics Contract Manufacturing Demand Share Analysis (%), By Platform, 2020-2030
  • Figure 12: Global Biologics Contract Manufacturing Demand Y-o-Y Analysis (%), By Platform, 2020-2030
  • Figure 13: Global Biologics Contract Manufacturing Demand Capacity Attractiveness Analysis By Platform, 2020-2030
  • Figure 14: Global Biologics Contract Manufacturing Demand Share Analysis (%), By Therapeutic Area, 2020-2030
  • Figure 15: Global Biologics Contract Manufacturing Demand Y-o-Y Analysis (%), By Therapeutic Area, 2020-2030
  • Figure 16: Global Biologics Contract Manufacturing Demand Capacity Attractiveness Analysis By Therapeutic Area, 2020-2030
  • Figure 17: Global Biologics Contract Manufacturing Demand Share Analysis (%), By Application, 2020-2030
  • Figure 18: Global Biologics Contract Manufacturing Demand Y-o-Y Analysis (%), By Application, 2020-2030
  • Figure 19: Global Biologics Contract Manufacturing Demand Capacity Attractiveness Analysis By Application, 2020-2030
  • Figure 20: Global Biologics Contract Manufacturing Demand Share Analysis (%), By Region, 2020-2030
  • Figure 21: Global Biologics Contract Manufacturing Demand Y-o-Y Analysis (%), By Region, 2020-2030
  • Figure 22: Global Biologics Contract Manufacturing Demand Capacity Attractiveness Analysis By Region, 2020-2030
  • Figure 23: North America Biologics Contract Manufacturing Demand Capacity Share, By Product, 2020 (E)
  • Figure 24: North America Biologics Contract Manufacturing Demand Capacity Share, By Platform, 2020 (E)
  • Figure 25: North America Biologics Contract Manufacturing Demand Capacity Share, By Therapeutic Area, 2020 (E)
  • Figure 26: North America Biologics Contract Manufacturing Demand Capacity Share, By Application, 2020 (E)
  • Figure 27: North America Biologics Contract Manufacturing Demand Capacity Share, By Country, 2020 (E)
  • Figure 28: North America Biologics Contract Manufacturing Demand Capacity (kL) Analysis, 2015-2019
  • Figure 29: North America Biologics Contract Manufacturing Demand Capacity Forecast (kL), 2020-2030
  • Figure 30: North America Biologics Contract Manufacturing Demand Value Analysis (US$ Mn), 2015-2019
  • Figure 31: North America Biologics Contract Manufacturing Demand Value Forecast (US$ Mn), 2020-2030
  • Figure 32: Latin America Biologics Contract Manufacturing Demand Capacity Share, By Product, 2020 (E)
  • Figure 33: Latin America Biologics Contract Manufacturing Demand Capacity Share, By Platform, 2020 (E)
  • Figure 34: Latin America Biologics Contract Manufacturing Demand Capacity Share, By Therapeutic Area, 2020 (E)
  • Figure 35: Latin America Biologics Contract Manufacturing Demand Capacity Share, By Application, 2020 (E)
  • Figure 36: Latin America Biologics Contract Manufacturing Demand Capacity Share, By Country, 2020 (E)
  • Figure 37: Latin America Biologics Contract Manufacturing Demand Capacity (kL) Analysis, 2015-2019
  • Figure 38: Latin America Biologics Contract Manufacturing Demand Capacity Forecast (kL), 2020-2030
  • Figure 39: Latin America Biologics Contract Manufacturing Demand Value Analysis (US$ Mn), 2015-2019
  • Figure 40: Latin America Biologics Contract Manufacturing Demand Value Forecast (US$ Mn), 2020-2030
  • Figure 41: Europe Biologics Contract Manufacturing Demand Capacity Share, By Product, 2020 (E)
  • Figure 42: Europe Biologics Contract Manufacturing Demand Capacity Share, By Platform, 2020 (E)
  • Figure 43: Europe Biologics Contract Manufacturing Demand Capacity Share, By Therapeutic Area, 2020 (E)
  • Figure 44: Europe Biologics Contract Manufacturing Demand Capacity Share, By Application, 2020 (E)
  • Figure 45: Europe Biologics Contract Manufacturing Demand Capacity Share, By Country, 2020 (E)
  • Figure 46: Europe Biologics Contract Manufacturing Demand Capacity (kL) Analysis, 2015-2019
  • Figure 47: Europe Biologics Contract Manufacturing Demand Capacity Forecast (kL), 2020-2030
  • Figure 48: Europe Biologics Contract Manufacturing Demand Value Analysis (US$ Mn), 2015-2019
  • Figure 49: Europe Biologics Contract Manufacturing Demand Value Forecast (US$ Mn), 2020-2030
  • Figure 50: South Asia Biologics Contract Manufacturing Demand Capacity Share, By Product, 2020 (E)
  • Figure 51: South Asia Biologics Contract Manufacturing Demand Capacity Share, By Platform, 2020 (E)
  • Figure 52: South Asia Biologics Contract Manufacturing Demand Capacity Share, By Therapeutic Area, 2020 (E)
  • Figure 53: South Asia Biologics Contract Manufacturing Demand Capacity Share, By Application, 2020 (E)
  • Figure 54: South Asia Biologics Contract Manufacturing Demand Capacity Share, By Country, 2020 (E)
  • Figure 55: South Asia Biologics Contract Manufacturing Demand Capacity (kL) Analysis, 2015-2019
  • Figure 56: South Asia Biologics Contract Manufacturing Demand Capacity Forecast (kL), 2020-2030
  • Figure 57: South Asia Biologics Contract Manufacturing Demand Value Analysis (US$ Mn), 2015-2019
  • Figure 58: South Asia Biologics Contract Manufacturing Demand Value Forecast (US$ Mn), 2020-2030
  • Figure 59: East Asia Biologics Contract Manufacturing Demand Capacity Share, By Product, 2020 (E)
  • Figure 60: East Asia Biologics Contract Manufacturing Demand Capacity Share, By Platform, 2020 (E)
  • Figure 61: East Asia Biologics Contract Manufacturing Demand Capacity Share, By Therapeutic Area, 2020 (E)
  • Figure 62: East Asia Biologics Contract Manufacturing Demand Capacity Share, By Application, 2020 (E)
  • Figure 63: East Asia Biologics Contract Manufacturing Demand Capacity Share, By Country, 2020 (E)
  • Figure 64: East Asia Biologics Contract Manufacturing Demand Capacity (kL) Analysis, 2015-2019
  • Figure 65: East Asia Biologics Contract Manufacturing Demand Capacity Forecast (kL), 2020-2030
  • Figure 66: East Asia Biologics Contract Manufacturing Demand Value Analysis (US$ Mn), 2015-2019
  • Figure 67: East Asia Biologics Contract Manufacturing Demand Value Forecast (US$ Mn), 2020-2030
  • Figure 68: Oceania Biologics Contract Manufacturing Demand Capacity Share, By Product, 2020 (E)
  • Figure 69: Oceania Biologics Contract Manufacturing Demand Capacity Share, By Platform, 2020 (E)
  • Figure 70: Oceania Biologics Contract Manufacturing Demand Capacity Share, By Therapeutic Area, 2020 (E)
  • Figure 71: Oceania Biologics Contract Manufacturing Demand Capacity Share, By Application, 2020 (E)
  • Figure 72: Oceania Biologics Contract Manufacturing Demand Capacity Share, By Country, 2020 (E)
  • Figure 73: Oceania Biologics Contract Manufacturing Demand Capacity (kL) Analysis, 2015-2019
  • Figure 74: Oceania Biologics Contract Manufacturing Demand Capacity Forecast (kL), 2020-2030
  • Figure 75: Oceania Biologics Contract Manufacturing Demand Value Analysis (US$ Mn), 2015-2019
  • Figure 76: Oceania Biologics Contract Manufacturing Demand Value Forecast (US$ Mn), 2020-2030
  • Figure 77: Middle East & Africa (MEA) Biologics Contract Manufacturing Demand Capacity Share, By Product, 2020 (E)
  • Figure 78: Middle East & Africa (MEA) Biologics Contract Manufacturing Demand Capacity Share, By Platform, 2020 (E)
  • Figure 79: Middle East & Africa (MEA) Biologics Contract Manufacturing Demand Capacity Share, By Therapeutic Area, 2020 (E)
  • Figure 80: Middle East & Africa (MEA) Biologics Contract Manufacturing Demand Capacity Share, By Application, 2020 (E)
  • Figure 81: Middle East & Africa (MEA) Biologics Contract Manufacturing Demand Capacity Share, By Country, 2020 (E)
  • Figure 82: Middle East & Africa (MEA) Biologics Contract Manufacturing Demand Capacity (kL) Analysis, 2015-2019
  • Figure 83: Middle East & Africa (MEA) Biologics Contract Manufacturing Demand Capacity Forecast (kL), 2020-2030
  • Figure 84: Middle East & Africa (MEA) Biologics Contract Manufacturing Demand Value Analysis (US$ Mn), 2015-2019
  • Figure 85: Middle East & Africa (MEA) Biologics Contract Manufacturing Demand Value Forecast (US$ Mn), 2020-2030
  • Figure 86: U. S. Biologics Contract Manufacturing Demand Capacity (kL) Analysis, 2015-2019
  • Figure 87: U. S. Biologics Contract Manufacturing Demand Capacity Forecast (kL), 2020-2030
  • Figure 88: Canada Biologics Contract Manufacturing Demand Capacity (kL) Analysis, 2015-2019
  • Figure 89: Canada Biologics Contract Manufacturing Demand Capacity Forecast (kL), 2020-2030
  • Figure 90: U. K. Biologics Contract Manufacturing Demand Capacity (kL) Analysis, 2015-2019
  • Figure 91: U. K. Biologics Contract Manufacturing Demand Capacity Forecast (kL), 2020-2030
  • Figure 92: Germany Biologics Contract Manufacturing Demand Capacity (kL) Analysis, 2015-2019
  • Figure 93: Germany Biologics Contract Manufacturing Demand Capacity Forecast (kL), 2020-2030
  • Figure 94: France Biologics Contract Manufacturing Demand Capacity (kL) Analysis, 2015-2019
  • Figure 95: France Biologics Contract Manufacturing Demand Capacity Forecast (kL), 2020-2030
  • Figure 96: Spain Biologics Contract Manufacturing Demand Capacity (kL) Analysis, 2015-2019
  • Figure 97: Spain Biologics Contract Manufacturing Demand Capacity Forecast (kL), 2020-2030
  • Figure 98: Italy Biologics Contract Manufacturing Demand Capacity (kL) Analysis, 2015-2019
  • Figure 99: Italy Biologics Contract Manufacturing Demand Capacity Forecast (kL), 2020-2030